Lin BioScience Announces FDA Orphan Drug Designation for LBS-007 for the Treatment of Acute Lymphoblastic Leukemia

Cancer cell cycle inhibitor is Lin BioScience's second candidate to receive Orphan Drug Designation SAN DIEGO, April 24, 2018 -- (Healthcare Sales &Marketing Network) -- Lin BioScience, a drug development company targeting unmet clinical needs in onco... Biopharmaceuticals, Oncology, FDA Lin BioScience, LBS-007, acute lymphoblastic leukemia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

Authors: Skah S, Richartz N, Duthil E, Gilljam KM, Bindesbøll C, Naderi EH, Eriksen AB, Ruud E, Dirdal MM, Simonsen A, Blomhoff HK Abstract Autophagy is important in regulating the balance between cell death and survival, with the tumor suppressor p53 as one of the key components in this interplay. We have previously utilized an in vitro model of the most common form of childhood cancer, B cell precursor acute lymphoblastic leukemia (BCP-ALL), to show that activation of the cAMP signaling pathway inhibits p53-mediated apoptosis in response to DNA damage in both cell lines and primary leukemic cells. The pres...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
ConclusionsOur study revealed aberrant genetic aberrations in signaling networks that may contribute to race-specific aspects of leukemogenesis. Our results suggest the value of WES as a tool for development of individual gene signatures and gene scores for AA and EA children afflicted by B-ALL. These findings may ultimately impact disease management and contribute to the elimination of disparate outcomes in AA children with B-ALL.Graphical abstract
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: 13 August 2018Source: Cancer Cell, Volume 34, Issue 2Author(s): Marlies Vanden Bempt, Sofie Demeyer, Michaël Broux, Jolien De Bie, Simon Bornschein, Nicole Mentens, Roel Vandepoel, Ellen Geerdens, Enrico Radaelli, Beat C. Bornhauser, Andreas E. Kulozik, Jules P. Meijerink, Jean-Pierre Bourquin, Charles E. de Bock, Jan CoolsSummaryThe NUP214-ABL1 fusion is a constitutively activated tyrosine kinase that is significantly associated with overexpression of the TLX1 and TLX3 transcription factors in T cell acute lymphoblastic leukemia (T-ALL). Here we show that NUP214-ABL1 cooperates with TLX1 in dri...
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research
UCLA Health has joined an important national clinical trial that uses genetic testing to match people who have acute myeloid leukemia, or AML, with new therapies. UCLA ’s hospital system is the first in California to offer people the opportunity to participate.The Beat AML Master Trial will evaluate a precision-based medicine approach to treating the disease; it will allow people with the disease to have immediate access to new treatments that are currently in development without having to try more traditional approaches first. The approach could streamline a patient ’s course of treatment and, ultimately, save...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
Pediatric Blood&Cancer, EarlyView.
Source: Pediatric Blood and Cancer - Category: Cancer & Oncology Authors: Source Type: research
Rearrangements involving the neurotrophic receptor kinase genes (NTRK1, NTRK2, and NTRK3; hereafter referred to as TRK) produce oncogenic fusions in a wide variety of cancers in adults and children. Although TRK fusions occur in fewer than 1% of all solid tumors, inhibition of TRK results in profound therapeutic responses, resulting in Breakthrough Therapy FDA approval of the TRK inhibitor larotrectinib for adult and pediatric patients with solid tumors, regardless of histology. In contrast to solid tumors, the frequency of TRK fusions and the clinical effects of targeting TRK in hematologic malignancies are unknown. Here,...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
(University of Texas M. D. Anderson Cancer Center) Almost one year after the US Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapy for children with acute lymphoblastic leukemia (ALL), researchers at The University of Texas MD Anderson Cancer Center and the Pediatric Acute Lung Injury and Sepsis Investigators Network (PALISI) today published treatment guidelines for managing the treatment in the online issue of Nature Reviews Clinical Oncology.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Curry J, Featherston S, Foglesong J, Shoberu B, Gulbis A, Mireles ME, Hafemeister L, Nguyen C, Kapoor N, Rezvani K, Neelapu SS, Shpall EJ, Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network Abstract In 2017, an autologous chimeric antigen receptor (CAR) T cell therapy indicated for children and young adults with relapsed and/or refractory CD19+ acute lymphoblastic leukaemia became the first gene therapy to be approved in the USA. This innovative form of cellular immunotherapy has been associated with remarkable response rates but is also associated with unique and often severe toxicities, which ...
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: Nat Rev Clin Oncol Source Type: research
Publication date: August 2018Source: Seminars in Cancer Biology, Volume 51Author(s): Jessica Nordlund, Ann-Christine SyvänenAbstractAcute lymphoblastic leukemia (ALL) is the most common malignancy in children. ALL arises from the malignant transformation of progenitor B- and T-cells in the bone marrow into leukemic cells, but the mechanisms underlying this transformation are not well understood. Recent technical advances and decreasing costs of methods for high-throughput DNA sequencing and SNP genotyping have stimulated systematic studies of the epigenetic changes in leukemic cells from pediatric ALL patients. The re...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Conclusion: Silymarin decreased early Doxorubicin induced left ventricular systolic function disturbances and can be recommended as adjuvant drug in patients with ALL under doxorubicin therapy. RECOMMENDATION: Multicenter studies on large number of patients with longer duration of follow up to prove the protective effects of silymarin in early and late Doxorubicin induced cardiotoxicity. PMID: 30073931 [PubMed - as supplied by publisher]
Source: Infectious Disorders Drug Targets - Category: Infectious Diseases Authors: Tags: Infect Disord Drug Targets Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer | Cancer & Oncology | Leukemia | Marketing | Pharmaceuticals